{
    "Trade/Device Name(s)": [
        "Dexcom G6 Glucose Program Continuous Glucose Monitoring System",
        "Dexcom G6 Glucose Program Continuous Glucose Monitoring (CGM) System",
        "Dexcom Glucose Program System"
    ],
    "Submitter Information": "Dexcom, Inc.",
    "510(k) Number": "K192787",
    "Predicate Device Reference 510(k) Number(s)": [
        "K191450"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QDK"
    ],
    "Summary Letter Date": "October 25, 2019",
    "Summary Letter Received Date": "September 30, 2019",
    "Submission Date": "September 26, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated continuous glucose monitoring system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dexcom G6 Glucose Program System (sensor, transmitter, mobile app)"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Transmitter",
        "Mobile application",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom G6 Glucose Program CGM System using amperometric sensor and mobile app for real-time diabetes management.",
    "Indications for Use Summary": "Indicated for real-time management of diabetes in persons 2 years and older; intended to replace fingerstick testing for diabetes treatment decisions in persons not at significant risk of severe hypoglycemia and to aid detection of hyperglycemia and hypoglycemia.",
    "fda_folder": "Clinical Chemistry"
}